MARTINSRIED/MUNICH, Germany, Dec. 20 /PRNewswire-FirstCall/ -- U.S.
Research and Development Facilities in Waltham/Boston Mass. and Princeton N.J.
-- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB)
today announced that it will hold a conference call today, Tuesday, December
20, 2005 to discuss its partnering agreement with Pharmion Corporation. The
two companies announced earlier today that they have entered into a co-
development and license agreement for satraplatin.
The call will be held today at 15:30 CET/9:30 AM EST. Participants may
listen via live webcast, accessible through the GPC Biotech Web site at
http://www.gpc-biotech.com, or via telephone. A replay will be available via
the Web site following the live event.
The dial-in numbers for the call are as follows:
European participants: 0049-(0)69-500-71846
U.S. participants: 1-866-202-1971 (toll-free)
GPC Biotech AG is a biopharmaceutical company discovering and developing
new anticancer drugs. The Company's lead product candidate - satraplatin - has
achieved target enrolment in a Phase 3 registrational trial as a second-line
chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has
granted fast track designation to satraplatin for this indication, and GPC
Biotech has begun the rolling NDA submission process for this compound.
Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC biotech
is also developing a monoclonal antibody with a novel mechanism-of-action
against a variety of lymphoid tumors, currently in Phase 1 clinical
development, and has ongoing drug development and discovery programs that
leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered
in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary
has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional
information, please visit the Company's Web site at
http://www.gpc-biotech.com.
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com
CONTACT:
Martin Braendle, Associate Director, Investor
Relations & Corporate Communications, +49 (0)89 8565-2693,
ir@gpc-biotech.com, or Laurie Doyle, Associate Director, Investor
Relations & Corporate Communications, +1-781-890-9007 ext. 267,
usinvestors@gpc-biotech.com, both of GPC Biotech AG; or In the
U.S.: Matt Haines of Euro RSCG Life NRP, +1-212-845-4235,
matthew.haines@eurorscg.com; or In Europe: Brian Hudspith of
Maitland Noonan Russo, +44 (0)20 7379 5151,
bhudspith@maitland.co.uk
|
